中醫治療肝硬化合併肝癌之病例報告

Liver Cirrhosis and Hepatocellular Carcinoma Treated with Traditional Chinese Medicine-A Case Report

10.29810/SJTTCM.200804.0007

郭哲彰(Che-Chang Kuo)；洪曉嵐(Hsiao-Lan Hung)

肝硬化 ； 肝癌 ； 中藥 ； Liver Cirrhosis ； hepatoellular carcinoma ； Chinese herb

臺灣中醫科學雜誌

3卷1期（2008 / 04 / 20）

34 - 39

繁體中文

在台灣，20-40%肝硬化病人會演變成肝癌，60-90%肝癌病人本身就有肝硬化。此外，針對病毒性肝炎，80-90%肝癌病人是B肝帶原，10%是C肝帶原。本案例為60歲男性者，罹患B肝帶原且肝硬化合併肝癌，因血液中GPT居高不下，伴有全身倦怠，腹脹等症狀，經中醫治療後GPT戲劇性的下降，且AFP也下降到正常值。證實中醫在治療治療肝硬化合併肝癌，具有一定的療效。

In Taiwan, 20-40% of liver cirrhosis patients will affect hepatoma and 60-90% of hepatoma patients combine with liver cirrhosis. Moreover, 80-90% of hepatoma patients are Hepatitis B carriers and 10% of hepatoma patients are Hepatitis C carriers. In this reported case, there was a 60 years old male. He was a Hepatitis B carrier and affected liver cirrhosis and hepatocellular carcinoma. After treated with traditional Chinese medicine (TCM), the GTP level was reduced and the APF level descended to the normal value. These therapeutic effects confirm that the treatments of TCM are benefits for patient with liver cirrhosis and hepatocellular carcinoma.